LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity

31-01-2019
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for innovative projects focused on adding value to biomedical research. The effort wants to contribute to the discovery of drugs for diseases unmet needs, supporting the best biomedical science. Consequently, the Chemostart initiative (http://www.insudpharma.com/es/chemostart#colaboremos) is meant to promoting the best innovative projects. As a result of an extremely competitive assessment of hundreds of ventures, LeadArtis immune-oncology therapeutic project has nominated between the twelve finalist projects and invited to present at the final pitching day to be held on January 31st, 2019.  
 
LeadArtis is a preclinical stage health biotechnology company located in Madrid (www.leadartis.com) focused on developing tumor targeted multivalent and multispecific immune stimulating antibodies through its unique Trimerbody® technology. The Trimerbodies exhibit excellent antigen binding capacity, functionality and stability.

Latest News

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity
31-01-2019
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for...
LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity
08-11-2018
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018...
Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes
11-12-2018

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer...